Document is current

Article History

Received: 15 January 2025

Accepted: 5 April 2025

First Online: 26 May 2025

Declarations

:

: T. Reiberger received grant support from Abbvie, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Myr Pharmaceuticals, Philips Healthcare, Pliant, Siemens and W. L. Gore & Associates; speaking/writing honoraria from Abbvie, Echosens, Gilead, GSK, Intercept/Advanz Pharma, Pfizer, Roche, MSD, Siemens, W. L. Gore & Associates; consulting/advisory board fee from Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Intercept/Advanz Pharma, MSD, Resolution Therapeutics, Siemens; and travel support from Abbvie, Boehringer Ingelheim, Dr. Falk Pharma, Gilead, and Roche. M. Trauner received grant support from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and UltraGenyx, honoraria for consulting from AbbVie, Albireo, Agomab, Boehringer Ingelheim, BiomX, Chemomab, Dexoligo Therapeutics, Falk, Genfit, Gilead, GSK, Hightide, Intercept, Ipsen, Jannsen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens and Shire, speaker fees from Albireo, Boehringer Ingelheim, Bristol-Myers Squibb, Falk, Gilead, Ipsen, Intercept, MSD and Madrigal, as well as travel support from AbbVie, Falk, Gilead, Jannsen and Intercept. He is also co-inventor of patents on the medical use of 24-norursodeoxycholic acid filed by the Medical University of Graz. P. Haselwanter, S. Fairfield, M. Riedl-Wewalka, M. Schmid, A. F. Stättermayer, C. Zauner and M. Schneeweiss-Gleixner declare that they have no competing interests.

: The study was conducted according to the guidelines of the Declaration of Helsinki. It was approved by the local Ethics Committee of the Medical University of Vienna with the Ethics committee number: 1229/2024. Moreover, the responsible ethics committee waived the informed consent requirement, due to the retrospective setting of the study design.